Discontinued — last reported Q1 '19
Eli Lilly Available-for-Sale Debt Securities - Fair Value (Maturing 6 to 10 Years) decreased by 37.7% to $63.80M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 36.7%, from $100.80M to $63.80M.
afs_debt_securities_fair_value_maturing_6_to_10y| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $128.10M | $153.40M | $110.70M | $109.00M | $121.00M | $115.50M | $117.00M | $109.40M | $98.30M | $115.50M | $100.80M | $124.10M | $102.40M | $63.80M |
| QoQ Change | — | +19.8% | -27.8% | -1.5% | +11.0% | -4.5% | +1.3% | -6.5% | -10.1% | +17.5% | -12.7% | +23.1% | -17.5% | -37.7% |
| YoY Change | — | — | — | -14.9% | -21.1% | +4.3% | +7.3% | -9.6% | -14.9% | -1.3% | -7.9% | +26.2% | -11.3% | -36.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.